Latest Series A Funding Rounds
Companies raising their first major institutional growth round, from the product they sell to the investors backing their next stage.
- Rounds
- 1,140 All time
- Disclosed funding
- $47.7B 980 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
TucuviCompany profile Tucuvi provides conversational AI for clinical patient follow-up and monitoring. Tucuvi provides conversational AI for clinical patient follow-up and monitoring. | $20M | Series A | AI | Spain | Investors | |
| SA Spangle AICompany profile Builds agentic infrastructure layer connecting AI-led discovery to real-time conversion for commerce Builds agentic infrastructure layer connecting AI-led discovery to real-time conversion for commerce | $15M | Series A | AI | United States | Investors | |
| ED Enhanced Digital Group Inc.Company profile Provides derivatives solutions in the digital asset space for institutional clients Provides derivatives solutions in the digital asset space for institutional clients | Undisclosed | Series A | Fintech | United States | Investors | |
| V Builds technologies for spatial biology and multi-omics innovation | $48M | Series A | Biotech | United States | Investors | |
BrightHeartCompany profile BrightHeart develops AI software for prenatal ultrasound and fetal-heart screening. BrightHeart develops AI software for prenatal ultrasound and fetal-heart screening. | €11M | Series A | AI | France | Investors | |
| PT Poplar TherapeuticsCompany profile Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions | $50M | Series A | Healthtech | United States | Investors | |
| PS Provides AI-native due diligence for life sciences dealmaking | $20M | Series A | Biotech | United States | Investors | |
| SM Develops a Pulmonary Neuromodulation System for asthma treatment | $67M | Series A | Healthtech | United States | Investors | |
| CH Corsera HealthCompany profile Develops preventive RNAi medicines for cardiovascular disease prediction and prevention Develops preventive RNAi medicines for cardiovascular disease prediction and prevention | $80M | Series A | Healthtech | United States | Investors | |
ArenaCompany profile Arena evaluates AI models through comparisons and observations of how people use them in real tasks. Arena evaluates AI models through comparisons and observations of how people use them in real tasks. | $150M | Series A | AI | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1Y Combinator (YC)
Palomma, Easol, Vera Health
56rounds0led - 2Andreessen Horowitz (a16z)
Larridin, Eka Robotics, TypeSafe AI
35rounds10led - 3General Catalyst
Onodrim Industries, Hyperbolic, Baba
28rounds2led - 4Accel
Humyn Labs, Dreamteam, SE3
25rounds8led - 5Alumni Ventures
Larridin, Chariot Claims, RegCell, Inc.
24rounds0led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.